Search results for "MESH : Adolescent"

showing 5 items of 15 documents

VEB-1 in Achromobacter xylosoxidans from Cystic Fibrosis Patient, France

2006

Multidrug-resistant Achromobacter xylosoxidans was recovered from the sputum of a patient with cystic fibrosis. The VEB-1 extended-spectrum β-lactamase was detected on a class 1 integron. This first report of a VEB-1–producing isolate in this population requires further investigation to determine its distribution.

MaleMESH : Molecular Sequence DataintegronMESH: beta-Lactamaseslcsh:MedicineMESH: Base Sequence[ SDV.MP.BAC ] Life Sciences [q-bio]/Microbiology and Parasitology/BacteriologyIntegronCystic fibrosisIntegronscystic fibrosisComputingMilieux_MISCELLANEOUSMESH: Microbial Sensitivity Tests0303 health scienceseducation.field_of_studybiologyEscherichia coli ProteinsMESH : beta-LactamasesAchromobacter denitrificansdispatchAchromobacter xylosoxidansMESH: Integrons3. Good healthMESH : Achromobacter denitrificansFrancemedicine.symptomAchromobacter xylosoxidansMESH : IntegronsMESH: Cystic FibrosisAdolescentMESH : MaleMolecular Sequence DataPopulationMicrobial Sensitivity Testsbeta-LactamasesMicrobiologylcsh:Infectious and parasitic diseases03 medical and health sciencesMESH : AdolescentMESH : Cystic FibrosismedicineHumansBase sequencelcsh:RC109-216education030304 developmental biologyMESH: AdolescentMESH: HumansMESH: Molecular Sequence DataBase Sequence030306 microbiologybusiness.industryMESH : Humanslcsh:RExtended-spectrum beta-lactamase VEB-1biology.organism_classificationmedicine.disease[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/BacteriologyMESH: MaleMESH: Achromobacter denitrificansAchromobacter denitrificansbiology.proteinSputumMESH : Base SequenceMESH : Microbial Sensitivity Tests[SDV.MP.BAC] Life Sciences [q-bio]/Microbiology and Parasitology/BacteriologybusinessEmerging Infectious Diseases
researchProduct

[Cost of hospital-based management of acute myeloid leukemia: from analytical to procedure-based tarification]

2006

International audience; The confrontation of the macro- and micro-economic approaches of hospital costs is a recurrent question, in particular for pathologies where length of stay is highly variable, like acute myeloid leukemias (AML). This monocentric and retrospective study compares direct hospital medical costs of induction and relapse treatment sequences for AML, valued according to four different approaches: the analytic accounting system of our hospital, the French Diagnosis Related Group (DRG) cost databases of hospital discharges (readjusted, or not, to actual hospital stay duration), and official tariffs from the new French DRG prospective payment system. The average cost of hospit…

MaleMESH: Remission InductionMESH : Retrospective StudiesMESH : RecurrenceMESH: Leukemia MyeloidMESH: Length of StayRecurrence[ SDV.IMM ] Life Sciences [q-bio]/ImmunologyMESH : FemaleHospital Costshealth care economics and organizationsMESH: Diagnosis-Related GroupsMESH: Hospital CostsMESH: Middle AgedRemission InductionMESH : Acute DiseaseMiddle AgedMESH : AdultMESH : Diagnosis-Related GroupsMESH : Length of StayLeukemia MyeloidAcute DiseaseMESH : Leukemia MyeloidMESH: Acute Disease[SDV.IMM]Life Sciences [q-bio]/ImmunologyFemaleMESH : Prospective Payment SystemFranceAdultAdolescent[SDV.IMM] Life Sciences [q-bio]/ImmunologyMESH : MaleMESH : Hospital CostsMESH: Prospective Payment SystemMESH : AdolescentHumansMESH : Middle AgedMESH : FranceDiagnosis-Related GroupsRetrospective StudiesMESH: AdolescentMESH : Remission InductionMESH: HumansProspective Payment SystemMESH : HumansMESH: Retrospective StudiesMESH: AdultLength of StayMESH: MaleMESH: RecurrenceMESH: FranceMESH: Female
researchProduct

Contribution of molecular analyses in diagnosing Marfan syndrome and type I fibrillinopathies: an international study of 1009 probands.

2008

International audience; BACKGROUND: The diagnosis of Marfan syndrome (MFS) is usually initially based on clinical criteria according to the number of major and minor systems affected following international nosology. The number of FBN1 mutation carriers, at risk of aortic complications who would not be properly diagnosed based only on clinical grounds, is of growing importance owing to the increased availability of molecular screening. The aim of the study was to identify patients who should be considered for FBN1 mutation screening. METHODS: Our international series included 1009 probands with a known FBN1 mutation. Patients were classified as either fulfilling or not fulfilling "clinical"…

ProbandNosologyMarfan syndromeMalePediatricsSystemic diseaseMESH : International CooperationFibrillin-1International CooperationMESH : Aged[SDV.GEN] Life Sciences [q-bio]/GeneticsMarfan SyndromeMESH : ChildMESH: ChildEpidemiologyMESH : FemaleEctopia lentisChildGenetics (clinical)AortaAortic dissectionMESH: Aged0303 health sciences030305 genetics & heredityMicrofilament ProteinsMESH: AortaMESH : AdultConnective tissue disease3. Good healthFemaleMESH : Mutationmusculoskeletal diseasesAdultmedicine.medical_specialtycongenital hereditary and neonatal diseases and abnormalitiesMESH: MutationMESH : Microfilament ProteinsAdolescentMESH : MaleFibrillinsMESH: Marfan Syndrome03 medical and health sciencesMESH: Microfilament ProteinsMESH : AdolescentGeneticsmedicineHumans030304 developmental biologyAgedMESH: Adolescent[SDV.GEN]Life Sciences [q-bio]/GeneticsMESH : Marfan SyndromeMESH: Humansbusiness.industryMESH : HumansMESH : AortaMESH: Adultmedicine.diseaseMESH: MaleMESH: International CooperationMutation[ SDV.GEN ] Life Sciences [q-bio]/GeneticsbusinessMESH: FemaleJournal of medical genetics
researchProduct

Impact of viable CD45 cells infused on lymphocyte subset recovery after unrelated cord blood transplantation in children

2010

International audience; We studied lymphocyte recovery in 88 children who consecutively underwent unrelated cord blood transplantation for malignant (n = 64) or nonmalignant (n = 24) diseases. All children but 3 received myeloablative conditioning regimens with pretransplant antithymocyte globulin. Median age was 5.6 years (0.1-18 years) and median follow-up was 40 months (10-136 months). The median dose of infused viable CD45(+) cells (vCD45) was 3.35 × 10(7)/kg with a ratio infused vCD45/collected total nucleated cell at 0.46. Immunologic endpoints were: time to achieve CD3(+) >500 and 1500/mm(3), CD4(+) >500/mm(3), CD8(+) >250/mm(3), CD19(+) >200/mm(3), natural killer >100/mm(3). These e…

[SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/HematologyLymphocyteMESH: Antigens CD/analysisCell Count[SDV.GEN] Life Sciences [q-bio]/GeneticsMESH : Child PreschoolGastroenterology0302 clinical medicineMESH : ChildMESH: Child[ SDV.MHEP.HEM ] Life Sciences [q-bio]/Human health and pathology/Hematology[ SDV.IMM ] Life Sciences [q-bio]/ImmunologyChildChildrenMESH : Lymphocyte Count0303 health sciencesMESH : Cell SurvivalbiologyIncidence (epidemiology)Graft Survival[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/HematologyHematology3. Good healthMESH: Hematologic Diseases/therapy Humansmedicine.anatomical_structureQuartileMESH: Cell SurvivalMESH: Cord Blood Stem Cell Transplantation/methodsLymphocytes recoveryChild PreschoolMESH : Immunophenotyping[SDV.IMM]Life Sciences [q-bio]/ImmunologyMESH: Infant KineticsCord Blood Stem Cell Transplantationmedicine.medical_specialtyMESH: Lymphocyte CountGlobulinMESH: ImmunophenotypingAdolescent[SDV.IMM] Life Sciences [q-bio]/ImmunologyCell SurvivalContext (language use)MESH : Hematologic Diseases/therapy HumansCD19Immunophenotyping03 medical and health sciencesMESH : Lymphocyte Subsets/cytologyAntigens CDInternal medicineMESH : AdolescentmedicineHumansLymphocyte CountMESH : Infant KineticsMESH : Antigens CD45* Cell Count030304 developmental biologyMESH: AdolescentTransplantation[SDV.GEN]Life Sciences [q-bio]/GeneticsUmbilical cord blood transplantationMESH : Graft Survival/immunologybusiness.industryUmbilical Cord Blood TransplantationMESH: Child PreschoolMESH : Cord Blood Stem Cell Transplantation/methodsInfantMESH : Antigens CD/analysisHematologic DiseasesLymphocyte SubsetsSurgeryMESH: Lymphocyte Subsets/cytologyKineticsbiology.proteinMESH: Antigens CD45* Cell CountLeukocyte Common Antigensbusiness[ SDV.GEN ] Life Sciences [q-bio]/GeneticsMESH: Graft Survival/immunologyCD8030215 immunology
researchProduct

Factors related to the relative survival of patients with diffuse large B-cell lymphoma in a population-based study in France: does socio-economic st…

2017

IF 7.702; International audience; The survival of patients with diffuse large B-cell lymphoma has increased during the last decade as a result of addition of anti-CD20 to anthracycline-based chemotherapy. Although the trend is encouraging, there are persistent differences in survival within and between the USA and European countries suggesting that non-biological factors play a role. Our aim was to investigate the influence of such factors on relative survival of patients with diffuse large B-cell lymphoma. We conducted a retrospective, multicenter, registry-based study in France on 1165 incident cases of diffuse large B-cell lymphoma between 2002 and 2008. Relative survival analyses were p…

[SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/HematologyMale0301 basic medicinePediatricsMultivariate analysisMESH: RegistriesMESH : AgedMESH: ComorbidityComorbidityMESH : Lymphoma Large B-Cell DiffuseMESH: Aged 80 and over0302 clinical medicineInternational Prognostic IndexMESH : ChildMESH: ChildMESH : Population Surveillance[ SDV.MHEP.HEM ] Life Sciences [q-bio]/Human health and pathology/HematologyMESH : FemaleRegistriesYoung adultChildAged 80 and overMESH: AgedMESH: Middle AgedMESH : PrognosisRelative survivalMESH: Patient Outcome Assessment[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/HematologyArticlesHematologyMiddle AgedMESH : AdultPrognosisMESH : Patient Outcome Assessment3. Good healthMESH: Young AdultPopulation SurveillanceMESH: Survival Analysis030220 oncology & carcinogenesisMESH : ComorbidityMarital statusFemaleFranceLymphoma Large B-Cell DiffuseNon-Hodgkin LeukemiaAdultmedicine.medical_specialtyAdolescentMESH : MaleMESH: Factor Analysis StatisticalMESH : Young AdultMESH : Factor Analysis StatisticalMESH: PrognosisMESH: Population SurveillanceMESH: Social ClassYoung Adult03 medical and health sciencesMESH : AdolescentInternal medicineMESH : Social ClassmedicineHumansMESH : Middle AgedMESH : Aged 80 and overMESH : FranceSurvival analysisAgedMESH: AdolescentMESH: Humansbusiness.industryMESH : HumansMESH: Adultmedicine.diseaseSurvival AnalysisComorbidityMESH: MalePatient Outcome AssessmentMESH: France030104 developmental biologySocial ClassMESH: Lymphoma Large B-Cell DiffuseMESH : Survival AnalysisFactor Analysis StatisticalbusinessMESH: FemaleDiffuse large B-cell lymphomaMESH : RegistriesHaematologica
researchProduct